Changes to Roche’s enlarged corporate executive committee

Swiss pharma giant Roche (ROG: SIX) on Monday announced today that James Sabry, head of Roche pharma partnering, will be retiring after 14 years with the company.

Mr Sabry joined Genentech in 2010 as head of Genentech partnering. In 2018, he became the head of pharma partnering and a member of the enlarged corporate executive committee, based in Basel, the headquarters of Roche which had acquired Genentech.

Boris Zaïtra, currently head of group business development, will be appointed head of corporate business development effective July 1, 2024, a new role that will bring together the pharma partnering and group business development functions. He will become a member of the enlarged corporate executive committee, reporting to Thomas Schinecker, group chief executive, and will continue to be based in Basel.